PMID- 26523780
OWN - NLM
STAT- MEDLINE
DCOM- 20160916
LR  - 20220317
IS  - 1873-1899 (Electronic)
IS  - 0734-9750 (Linking)
VI  - 33
IP  - 8
DP  - 2015 Dec
TI  - Peptide vaccines in breast cancer: The immunological basis for clinical response.
PG  - 1868-77
LID - S0734-9750(15)30048-3 [pii]
LID - 10.1016/j.biotechadv.2015.10.013 [doi]
AB  - This review discusses peptide-based vaccines in breast cancer, immune responses 
      and clinical outcomes, which include studies on animal models and phase I, phase 
      I/II, phase II and phase III clinical trials. Peptide-based vaccines are powerful 
      neoadjuvant immunotherapies that can directly target proteins expressed in tumor 
      cells, mainly tumor-associated antigens (TAAs). The most common breast cancer TAA 
      epitopes are derived from MUC1, HER2/neu and CEA proteins. Peptides derived from 
      TAAs could be successfully used to elicit CD8 and CD4 T cell-specific responses. 
      Thus, choosing peptides that adapt to natural variations of human leukocyte 
      antigen (HLA) genes is critical. The most attractive advantage is that the target 
      response is more specific and less toxic than for other therapies and vaccines. 
      Prominent studies on NeuVax - E75 (epitope for HER2/neu and GM-CSF) in breast 
      cancer and DPX-0907 (HLA-A2-TAAs) expressed in breast cancer, ovarian and 
      prostate cancer have shown the efficacy of peptide-based vaccines as neoadjuvant 
      immunotherapy against cancer. Future peptide vaccine strategies, although a 
      challenge to be applied in a broad range of breast cancers, point to the 
      development of degenerate multi-epitope immunogens against multiple targets.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Peres, Livia de Paula
AU  - Peres Lde P
AD  - Laboratorio de Osteoimunologia e Imunologia dos Tumores, Instituto de Ciencias 
      Biomedicas (ICBIM) - Universidade Federal de Uberlandia - UFU, Uberlandia, MG, 
      Brazil. Electronic address: lipperes23@gmail.com.
FAU - da Luz, Felipe Andres Cordero
AU  - da Luz FA
AD  - Laboratorio de Osteoimunologia e Imunologia dos Tumores, Instituto de Ciencias 
      Biomedicas (ICBIM) - Universidade Federal de Uberlandia - UFU, Uberlandia, MG, 
      Brazil.
FAU - Pultz, Brunna dos Anjos
AU  - Pultz Bdos A
AD  - Laboratorio de Osteoimunologia e Imunologia dos Tumores, Instituto de Ciencias 
      Biomedicas (ICBIM) - Universidade Federal de Uberlandia - UFU, Uberlandia, MG, 
      Brazil.
FAU - Brigido, Paula Cristina
AU  - Brigido PC
AD  - Laboratorio de Tripanossomatideos, Instituto de Ciencias Biomedicas (ICBIM) - 
      Universidade Federal de Uberlandia - UFU, Uberlandia, MG, Brazil.
FAU - de Araujo, Rogerio Agenor
AU  - de Araujo RA
AD  - Setor de Oncologia - Hospital de Clinicas de Uberlandia - UFU, Uberlandia, MG, 
      Brazil.
FAU - Goulart, Luiz Ricardo
AU  - Goulart LR
AD  - Laboratorio de Nanobiotecnologia - Universidade Federal de Uberlandia - UFU, 
      (INGEB), Uberlandia, MG, Brazil.
FAU - Silva, Marcelo Jose Barbosa
AU  - Silva MJ
AD  - Laboratorio de Osteoimunologia e Imunologia dos Tumores, Instituto de Ciencias 
      Biomedicas (ICBIM) - Universidade Federal de Uberlandia - UFU, Uberlandia, MG, 
      Brazil. Electronic address: majbsilva@icbim.ufu.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20151030
PL  - England
TA  - Biotechnol Adv
JT  - Biotechnology advances
JID - 8403708
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Epitopes)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Peptides)
RN  - 0 (Vaccines, Subunit)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Antigens, Neoplasm/*immunology
MH  - Breast Neoplasms/*immunology/prevention & control
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - Clinical Trials as Topic
MH  - Epitopes/immunology
MH  - Female
MH  - HLA-A2 Antigen/immunology
MH  - Humans
MH  - Peptides/*immunology/therapeutic use
MH  - Receptor, ErbB-2/antagonists & inhibitors/immunology
MH  - Vaccines, Subunit/*immunology/therapeutic use
OTO - NOTNLM
OT  - Breast cancer
OT  - Breast cancer immunotherapy
OT  - Breast cancer therapy
OT  - Peptide-based vaccines
OT  - Tumor-associated antigens
EDAT- 2015/11/03 06:00
MHDA- 2016/09/17 06:00
CRDT- 2015/11/03 06:00
PHST- 2015/04/18 00:00 [received]
PHST- 2015/10/15 00:00 [revised]
PHST- 2015/10/29 00:00 [accepted]
PHST- 2015/11/03 06:00 [entrez]
PHST- 2015/11/03 06:00 [pubmed]
PHST- 2016/09/17 06:00 [medline]
AID - S0734-9750(15)30048-3 [pii]
AID - 10.1016/j.biotechadv.2015.10.013 [doi]
PST - ppublish
SO  - Biotechnol Adv. 2015 Dec;33(8):1868-77. doi: 10.1016/j.biotechadv.2015.10.013. 
      Epub 2015 Oct 30.